CADTH

Appendix A: pCODR Clinician Conflict of Interest Declarations

Please note: Each registered clinician must complete their own separate pCODR Clinician Conflict of Interest Declarations Template even if the submission is made jointly.

Name of registered clinician:	John Kuruvilla	
Name of drug and indication under review:	BV + AVD for frontline treatment of Hodgkin lymphoma	

Conflict of Interest Declaration

To maintain the objectivity and credibility of the pCODR process, all participants in the pCODR review process must disclose any conflicts of interest. A registered clinician must declare any potential conflicts of interest that may influence or have the appearance of influencing the information submitted. A conflict of interest declaration is requested for transparency — it does not negate or preclude the use of the clinician input.

Examples of conflicts of interest include, but are not limited to:

- financial support from the pharmaceutical industry or other entities (e.g., educational or research grants, honoraria, gifts, and salary)
- affiliations, or personal or commercial relationships with drug manufacturers or other interest groups.

Section A: Payment Received

1. Have you received any payments over the previous two years from any company or organization that may have a direct or indirect interest in the drug under review?

⊠ Yes

□ No

If no, please go to Section B.

- 2. What form of payment did you receive? (Check all that apply.)
 - Advisory role (e.g., advisory boards, health technology assessment submission advice)
- Program or Operating Funding (e.g., website)
- □ Conference attendance Research/educational grants
- Royalties
- □ Gifts
- Honoraria

- □ Travel grants
- □ Sponsorship of events
- □ Other, please specify:
- 3. Please provide the names of companies and organizations, and the amounts of the payments, in the following table.



Company	Nature or description of activities or interests	Check Appropriate Dollar Range			
		\$0 to 5,000	\$5,001 to 10,000	\$10,001 to 50,000	In Excess of \$50,000
Seattle Genetics	Advisory boards, consulting		\boxtimes		

Section B: Holdings or Other Interests

Have you received or are in possession of stocks or options of more than \$10,000 (excluding mutual funds) for organizations that may have a direct or indirect interest in the drug under review? If yes, please list them in the following box.

Section C: Affiliations, Personal or Commercial Relationships

Do you have personal or commercial relationships either with a drug or health technology manufacturer (including the manufacturer's parent corporation, subsidiaries, affiliates, and associated corporations) or other interest groups? If yes, please provide the names of the companies and organizations, and outline the nature of these relationships, in the following box.

No

No

By checking this box, I hereby certify that the information that I have presented here is accurate and complete to the best of my knowledge.

16-Apr-2020

John Kuruvilla

Date

Name

Before completing this template, be sure to register with the pCODR program. Please visit https://www.cadth.ca/pcodr/registration for information about the registration process.

pCODR Clinician Conflict of Interest Declarations

Note: Each registered clinician must complete their own separate pCODR Clinician Conflict of Interest Declarations Template even if the submission is made jointly.

CADTH

PCODR PAN-CANADIAN ONCOLOGY DRUG REVIEW

Name of registered clinician: Graeme Fraser

Name of drug and indication under review: Brentuximab-vedotin/Adcetris + AVD for previously untreated HL

Conflict of Interest Declarations

To maintain the objectivity and credibility of the pCODR process, all participants in the pCODR review process must disclose any conflicts of interest. A registered clinician must declare any potential conflicts of interest that may influence or have the appearance of influencing the information submitted. Conflict of interest declaration is requested for transparency — it does not negate or preclude the use of the clinician input.

Examples of conflicts of interest include, but are not limited to:

- financial support from the pharmaceutical industry or other entities e.g., educational or research grants, honoraria, gifts, and salary;
- affiliations or personal or commercial relationships with drug manufacturers or other interest groups.

Section A: Payment Received

1. Have you received any payments over the previous two years from any company or organization that may have direct or indirect interest in the drug under review? Yes 🖾 No

If no, please go to Section B.

2. What form of payment did you receive? (Check all that apply.)

- Advisory role (e.g., advisory boards, Program or Operating Funding HTA submission advice) (e.g., website) Conference attendance
 - Research/educational grants Travel grants

Sponsorship of Events

- Royalties
- Gifts
- Honoraria
- Other, please specify: Click here to enter text.

3. Please provide the names of companies and organizations and the amounts of the payments in the box below.

П

Click here to enter text.

pCODR Clinician Input on a Drug Review

© February 2016 CADTH-pCODR | PAN-CANADIAN ONCOLOGY DRUG REVIEW

CADTH **FCODR** PAN-CANADIAN ONCOLOGY DRUG REVIEW

Before completing this template, be sure to register with the pCODR program. Please visit https://www.cadth.ca/pcodr/registration for information about the registration process.

Section B: Holdings or Other Interests

Have you received or is it in possession of stocks or options of more than \$10,000 (excluding mutual funds) for organizations that may have a direct or indirect interest in the drug under review? If yes, please list in the table below. No

Section C: Affiliations, personal or commercial relationships

Do you have personal or commercial relationships either with a drug or health technology manufacturer (including such manufacturer's parent corporation, subsidiaries, affiliates and associated corporations) or other interest groups? If yes, please provide the names of the companies and organizations and outline the nature of these relationships in the table below. No

I hereby certify that I have disclosed all relevant information with respect to any matter involving a Party that may place me in a real, potential or perceived conflict of interest situation.

Date:	April 14 th , 2020
Name:	Graeme Fraser
Signatur	

pCODR Clinician Input on a Drug Review

© February 2016 CADTH-pCODR | PAN-CANADIAN ONCOLOGY DRUG REVIEW

CADTH PAN-CANADIAN ONCOLOGY DRUG REVIEW

Before completing this template, be sure to <u>register</u> with the pCODR program. Please visit <u>https://www.cadth.ca/pcodr/registration</u> for information about the registration process.

pCODR Clinician Conflict of Interest Declarations

Note: Each registered clinician must complete their own separate pCODR Clinician Conflict of Interest Declarations Template even if the submission is made jointly.

Name of registered clinician: Click here to enter text. C. TOMKOUROUKLS

Name of drug and indication under review: Brentuximab AVD/HL

Conflict of Interest Declarations

To maintain the objectivity and credibility of the pCODR process, all participants in the pCODR review process must disclose any conflicts of interest. A registered clinician must declare any potential conflicts of interest that may influence or have the appearance of influencing the information submitted. Conflict of interest declaration is requested for transparency — it does not negate or preclude the use of the clinician input.

Examples of conflicts of interest include, but are not limited to:

- financial support from the pharmaceutical industry or other entities e.g., educational or research grants, honoraria, gifts, and salary;
- affiliations or personal or commercial relationships with drug manufacturers or other interest groups.

Section A: Payment Received

Have you received any payments over the previous two years from any company or organization that may have direct or indirect interest in the drug under review?
Yes

If no, please go to Section B.

- 2. What form of payment did you receive? (Check all that apply.)
 - Advisory role (e.g., advisory boards, HTA submission advice)
- Program or Operating Funding

□ Conference attendance

(e.g., website) Research/educational grants-

Sponsorship of Events

Travel grants

- □ Royalties
- □ Gifts
- Honoraria
- Other, please specify: Click here to enter text.
- 3. Please provide the names of companies and organizations and the amounts of the payments in the box below.

Click here to enter text.

Before completing this template, be sure to <u>register</u> with the pCODR program. Please visit <u>https://www.cadth.ca/pcodr/registration</u> for information about the registration process.

Section B: Holdings or Other Interests

Have you received or is it in possession of stocks or options of more than \$10,000 (excluding mutual funds) for organizations that may have a direct or indirect interest in the drug under review? If yes, please list in the table below.

CADT

DCC

PAN-CANADIAN ONCOLOGY DRUG REVIEW

Click here to enter text.

None

Section C: Affiliations, personal or commercial relationships

Do you have personal or commercial relationships either with a drug or health technology manufacturer (including such manufacturer's parent corporation, subsidiaries, affiliates and associated corporations) or other interest groups? If yes, please provide the names of the companies and organizations and outline the nature of these relationships in the table below.

Click here to enter text.

None

I hereby certify that I have disclosed all relevant information with respect to any matter involving a Party that may place me in a real, potential or perceived conflict of interest situation.

Date: Click here to enter text.

Name: Click here to enter text.

Signature: Click here to enter text.

С_	TOM	Fugues	st ZZ, ROUK	2019